Share on StockTwits

DexCom (NASDAQ:DXCM) Director Barbara Kahn unloaded 2,200 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $43.42, for a total value of $95,524.00. Following the completion of the sale, the director now directly owns 53,525 shares in the company, valued at approximately $2,324,056. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $41.00.

Shares of DexCom (NASDAQ:DXCM) traded down 1.36% during mid-day trading on Thursday, hitting $43.54. The stock had a trading volume of 692,515 shares. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock has a 50-day moving average of $39.65 and a 200-day moving average of $38.91. The company’s market cap is $3.286 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.